ZEPP heads into its May 20 Q1 2026 earnings release having lost nearly half its market value in a single week — a collapse that makes the upcoming print the only thing traders are watching.
The price move dominates everything else. Shares closed at $9.55 on May 12, down 15% on the day and 46% over the week. The month-long damage is 27%. This is a micro-cap stock — market cap around $140 million — so moves of this magnitude are not structurally unusual, but the speed is striking. The stock last suffered a comparable single-session hit in March 2026, when Q4 results triggered a 22-27% fall on the day, and the stock gave up a further 33% over the five days that followed. That prior earnings reaction is the clearest frame for what traders are now pricing in ahead of May 20.
The positioning story does not explain the move. Short interest has actually been drifting lower — down nearly 4% over the week to around 345,000 shares. The borrow market is loose: cost to borrow is a modest 3.6%, and it has eased 14% over the past month. Availability in the lending pool is wide open, with utilization sitting at just 21% — a far cry from its 52-week peak of 89%, which was registered when the borrow market was genuinely tight. Nothing in the short interest data suggests this week's selling was short-seller driven. It looks like long holders exiting.
Options traders are not positioned for further disaster, which is the most interesting divergence right now. The put/call ratio is running at 0.62, almost exactly in line with its 20-day average of 0.62. The z-score is effectively flat at -0.10 — not defensive, not speculative. The 52-week range for the PCR stretches from 0.57 to a remarkable 15.94, the latter reflecting an extraordinary episode of downside hedging that has since completely unwound. Against that backdrop, today's options market looks almost serene. Either options traders see the selloff as overdone, or the market for ZEPP options is simply too thin to carry meaningful information.
Ownership is heavily concentrated. Founder and CEO Wang Huang controls 30% of shares outstanding. Fidelity International added 91,596 shares to reach a 4.9% stake as of March 31. Point72, Millennium, and Balyasny all held positions as of year-end 2025. Mirae Asset is the most recently reported buyer, adding a fresh position as of April 30. State Street initiated a new position at year-end 2025. That institutional lineup — including two large hedge funds in Point72 and Millennium — adds context to the price action: forced selling from a small institutional holder in a thin-float stock can produce exactly this kind of gap.
On the fundamental side, Q4 2025 results showed genuine improvement. Revenue rose to $85 million from $60 million a year earlier, and the net loss narrowed sharply to $11 million versus $37 million. Full-year sales hit $259 million. The March print triggered a brutal market reaction despite those figures — down 22% the next day, down 33% over five days — which suggests the market had priced in something more. On the product side, the week brought a wave of Amazfit hardware news: the Cheetah 2 Pro trail running watch and Cheetah 2 Ultra were both announced, signalling the company remains active on new launches. Whether that pipeline carries any weight with investors at this price level is the question Q1 results will need to answer.
The ORTEX short score is at 49.4, sitting in neutral territory and fading from a brief move above 50 earlier this week. With the May 20 earnings call confirmed and the stock trading at a post-crash low, the next session that matters is the one immediately after the print — and how it compares to the 33% five-day wipeout that followed the last one.
See the live data behind this article on ORTEX.
Open ZEPP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
